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Abstract
Biomarkers for determining clearance ofMycobacterium tuberculosis (Mtb) infection dur-
ing anti-tuberculosis therapy or following exposure could facilitate enhanced monitoring
and treatment. We screened for biomarkers indicating clearance ofMtb infection in vitro.
A comparative proteomic analysis was performed using GeLC MSI/MS. Intracellular and
secreted proteomes from activated THP-1 cells infected with theMtb H37Rv strain (MOI
= 1) and treated with isoniazid and rifampicin for 1 day (infection stage) and 5 days (clear-
ance stage) were analyzed. Host proteins associated with early infection (n = 82), clear-
ance (n = 121), sustained in both conditions (n = 34) and suppressed by infection (n = 46)
were elucidated. Of the potential clearance markers, SSFA2 and CAECAM18 showed the
highest and lowest protein intensities, respectively. A western blot of CAECAM18 vali-
dated the LC MS/MS result. For three clearance markers (SSFA2, PARP14 and PSME4),
in vivo clinical validation was concordantly reported in previous patient cohorts. A network
analysis revealed that clearance markers were enriched amongst four protein interaction
networks centered on: (i) CD44/CCND1, (ii) IFN-β1/NF-κB, (iii) TP53/TGF-β and (iv) IFN-
γ/CCL2. After infection, proteins associated with proliferation, and recruitment of immune
cells appeared to be enriched possibly reflecting recruitment of defense mechanisms.
Counteracting proteins (CASP3 vs. Akt and NF-κB vs. TP53) associated with apoptosis
regulation and its networks were enriched among the early and sustained infection bio-
markers, indicating host-pathogen competition. The BRCA1/2 network was suppressed
during infection, suggesting that cell proliferation suppression is a feature ofMtb survival.
Our study provides insights into the mechanisms of host-Mtb interaction by comparing
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the stages of infection clearance. The identified clearance biomarkers may be useful in
monitoring tuberculosis treatment.
Introduction
Tuberculosis (TB) is one of the greatest public health problems. One-third of the global popula-
tion is infected withMycobacterium tuberculosis (Mtb), the causative agent of TB. Despite tre-
mendous efforts that have been directed toward controlling TB, TB still results in substantial
morbidity and mortality.
Assessing infection clearance remains challenging yet is central to TB control. First, infec-
tion clearance is likely a frequent outcome following exposure because only 10–50% of close
contacts with TB patients develop a positive tuberculin skin test (TST) and/or interferon
gamma release assay (IGRA) after exposure [1]. The TST/IGRA non-responders may represent
either persons who are truly unexposed toMtb infection or those who cleared infection
through an effective innate immune response or a localized immune response to infection
without a positive TST and/or IGRA [2, 3]. Understanding the mechanism of primary clear-
ance could assist in developing prophylactic interventions; however, identifying these individu-
als is challenging. Second, although TST/IGRAs are used to identify individuals with latent
infection who are at a 2-3-fold elevated risk for reactivation [4], treating a latent TB infection
does not result in TST/IGRA reversion [5]. Therefore, assessing latent TB treatment success is
not currently possible. Third, the treatment of active TB usually consists of combined drug
therapy for a minimum of 6 months for pulmonary disease or 9 months for extra-pulmonary
disease. Microbiological clearance is typically determined by clinical and radiological improve-
ment supplemented by sputum microscopy. However, microscopic analysis lacks sensitivity
even in patients with active disease and is likely to be even less sensitive in a partially treated
infection with low bacterial loads. The failure to achieve clearance may lead to relapse and to
drug resistance evolution. Moreover, the assessment of newer, shorter-course regimens in
development and testing [6, 7] would be aided by the availability of a reliable clearance marker.
Recent ‘omics’ studies have reported progress in identifying diagnostic biomarkers for active
TB and predictive biomarkers of incident TB [8]. These biomarkers have largely been cellular
or transcriptomic markers; however, protein biomarkers are among the first described [9]. Sub-
sequent proteomic studies have predominantly focused on identifying markers to diagnose
active disease [10–15]. In contrast, de Groote et al. [16] reported a targeted assessment of
serum proteins in patients with active disease whose expression changed following 8 weeks of
anti-TB therapy. However, the linkage to the microbiological response was not reported, the
sterilization of infection was not ensured, and the proteins that are differentially expressed
appear to be markers of reduced inflammation associated with clinical improvement, illustrat-
ing the complexities of biomarker discovery in complex organisms.
We screened for candidate biomarkers ofMtb clearance using an in vitro activated THP-1
cells model of treated TB infection and proteomic approaches.
Materials and Methods
THP-1 cell culture and activation
The human monocytic cell line THP-1 was cultured in RPMI 1640 supplemented with 2 mM
L-glutamine and 10% FBS (Hyclone, GE Healthcare Life Science, UK). THP-1 cells (1.5 x 106
cells/well) were activated using 50 nM/μl phorbol myristate acetate (PMA) and incubated at
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37°C in a 5% CO2 atmosphere for 24 hr. To reduce the effect of PMA from THP-1 cells, the
medium was replaced, and incubation was continued for another 24 hr.
Mtb culture and inoculum preparation
MtbH37Rv was grown in Middlebrook 7H9 with an OADC supplement for 14 days, adjusted
to 0.5 McFarland standards with PBS and diluted with RPMI medium.Mtb cell suspension dis-
persion was achieved by repeated passage through a 26-gauge needle set.
Infection experiments
After discarding the medium from THP-1 cells,MtbH37Rv (1.5 x 106 cells/well, MOI = 1) in
cRPMI suspension was immediately refilled and then incubated at 37°C in a 5% CO2 atmo-
sphere for 4 hr. After the infected cells were incubated, they were treated with 3 μg/ml isoniazid
(INH) and 9 μg/ml rifampicin (RIF) (optimized drug concentration for killingMtb within 3
days post-infection, which is consistent with microbiological clearance, S1 Table) in fresh
RPMI medium. These concentrations approximate therapeutic drug concentrations that accu-
mulate in patient serum [17]. Fresh drug-supplemented medium was fully exchanged every 24
hr until 5 days post-infection. The cell lysates and culture supernatants of the infected cells or
uninfected cells treated with the same anti-TB drugs were collected after 1 day (infection stage)
and 5 days (clearance stage) post-infection. We confirmed complete killing ofMtb in culture
using aliquots of each specimen (both intra- and extra-cellular preparations). By 3 days (72 hr)
post-infection, noMtb growth was detected by colony forming unit (CFU) determination.
Uninfected cells treated with anti-TB drugs were used as background controls. Three indepen-
dent experiments were performed on different days as biological replicates.
Proteome collection
Proteomes were collected from culture supernatants and cell lysates. For extracellular proteins,
3 ml of supernatant was collected from each well and filtered using a syringe filter (Whatman,
GE Healthcare Life Science, UK). For the intracellular proteins, the infected cells were washed
2 times with phosphate-buffered saline (PBS) and scraped off using 500 μl PBS/well and trans-
ferred into conical tubes. Then, SDS (0.5% w/v) was added and incubated for 5 min, and the
cells were sonicated at 53 KHz at 37°C for 30 min.
Protein extraction and preparation
Two volumes of acetone were added to the culture supernatants and cell lysate suspensions.
Protein suspensions were incubated at -20°C for 8 hr and then centrifuged at 8,000×g for 30
min at 4°C. Dried protein pellets were resuspended in 30 μl of sample storage buffer (50 mM
NaH2PO4, 5 mM DTT, 0.25 M NaCl solution and proteinase inhibitor). The quantities of the
extracted proteins were measured using the Lowry method. Five microliters each of protein
standard (0, 2, 4, 6, 8, 10 μg/ml BSA) and samples was transferred into 96-well plates (tripli-
cate), and 200 μl of solution A (2.5% SDS, 2.5% Na2CO3, 0.2 N NaOH, 0.025% CuSO4 and
0.05% tartaric acid) was added, and the plates were incubated for 30 min at room temperature.
Then, 50 μl of solution B (20% Folin-Ciocalteu phenol reagent) was added, and the plates were
incubated for 30 min at room temperature. Finally, the protein concentrations were measured
at OD750 and calculated by comparison with the standards.
Proteomic Analysis for Tuberculosis Clearance Markers
PLOS ONE | DOI:10.1371/journal.pone.0134168 July 27, 2015 3 / 16
SDS-PAGE and in-gel digestion
Fifty micrograms of protein was mixed with loading dye (77 mg/ml DTT, 0.1 g/ml SDS, 0.1
mg/ml bromophenol blue, 70% glycerol, and 0.4 M Tris, pH 6.8). Protein samples were sepa-
rated by SDS-PAGE and stained with Coomassie blue. The gel was sliced into 15–18 pieces,
and each gel plug was further cut into 1-mm3 cubes and transferred into low binding 96-well
plates. Tryptic digestion was performed by incubating the gel pieces with 25 mMNH4HCO3
for 10 min, adding 200 μl of acetonitrile (ACN) and incubating for 10 min with shaking. After
ACN removal, 50 μl of 10 mM DTT in 10 mMNH4HCO3 was added, and the gel pieces were
incubated at 56°C for 1 hr. Next, 50 μl of 100 mM iodoacetamide in 10 mMNH4HCO3 was
added, and then, the gel pieces were incubated at room temperature for 1 hr in the dark. Then,
all liquid was removed. Next, 2 cycles of adding 200 μl of ACN to the gel pieces and shaking for
5 min were performed, followed by the removal of all liquid. Enzymatic digestion was per-
formed by adding 10 μl of enzyme solution (10 ng/μl trypsin in 10 mMNH4HCO3) to the gel
pieces and incubating at 37°C for 3 hr. The peptide was extracted by 3 cycles of adding 50 μl of
50% ACN to the gel pieces and shaking at room temperature for 10 min. Finally, the peptide
solutions were transferred into new low binding 96-well plates and dried at 40°C. The dry pep-
tides were kept at -20°C until analysis.
LCMS/MS analysis
The peptide samples were resuspended in 0.1% formic acid, mixed with a pipette 100 times
and transferred into low-binding tubes. The samples were centrifuged at 8,000×g for 10 min
and transferred into vial tubes. Then, 4.5 μl of peptide sample was injected into a LC MS/MS
analyzer (SYNAPT HDMS mass spectrometer, Waters, UK). Nanoscale LC separation of tryp-
tic peptides was performed using a nanoACQUITY system equipped with a Symmetry C18
5 μm, 180 μm x 20 mm Trap column and a BEH130 C18 1.7 μm, 100 μm x 100 mm analytical
reversed phase column. The samples were initially transferred with mobile phase A solution
(0.1% formic acid) added to the trap column at a flow rate of 15 μl/min for 1 min. The peptides
were separated with a gradient of 15–50% mobile phase B solution (0.1% formic acid in aceto-
nitrile) for 15 min at a flow rate of 600 nl/min, followed by a 3-min rinse with 80% mobile
phase B. The column temperature was maintained at 35°C. The lock mass was delivered from
the auxiliary pump of the nanoACQUITY pump with a constant flow rate of 500 nl/min at a
concentration of 200 fmol/μl fibrinopeptide B to the reference sprayer of the NanoLockSpray
source of the machine. For all measurements, the mass spectrometer was operated in the V-
mode of analysis with a resolution of at least 10,000 full-width half-maximum. All analyses
were performed using the positive nanoelectrospray ion mode. The time-of-flight analyzer of
the mass spectrometer was externally calibrated with fibrinopeptide B from 50 to 1600 m/z
with acquisition lock mass corrected using the monoisotopic mass of the doubly charged pre-
cursor of [Glu1], a fibrinopeptide B. The reference sprayer was sampled at a frequency of 20
sec. The trap energy was set at a collision energy of 6 V. In the transfer collision energy control,
low energy was set at 4 V. The quadrupole mass analyzer was adjusted such that ions from m/z
300 to 1800 were efficiently transmitted. The MS/MS survey was over the range 50 to 1,990 Da
and 0.5 sec scan time. The values were normalized using a BSA external intensity control.
Western blot analysis
Protein samples (75 μg) were analyzed by 12.5% SDS-PAGE. The proteins were transferred
onto nitrocellulose membranes (0.2 μm, Bio-Rad, USA) using blotting buffer (7.25 mg/ml Tris
base, 3.6 mg/ml glycine, and 0.5 mg/ml SDS) and a blotting machine (Trans-Blot SD semi-dry
transfer cell, Bio-Rad, USA) at 18 V for 30 min. The protein-containing membranes were
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washed twice for 5 min with PBS-Tween solution. The blotted membranes were blocked using
5% skim milk in a PBS-Tween solution at 4°C overnight. The specific proteins were detected by
adding a primary antibody solution (rabbit anti-CAECAM at 1:500 dilution (Abcam, UK) and
mouse anti-β-actin at 1:3,000 dilution (Sigma, USA)) to the blotted membranes, incubating for
10 hr and washing three times for 5 min each with a PBS-Tween solution. The secondary anti-
body solution (HRP-conjugated anti-β-actin (Abcam, UK) and anti-rabbit IgG for anti-CAE-
CAM (Sigma, USA) at 1:1,000 dilution) was added to the blots, incubated for 2 hr and washed
three times for 5 min each with a PBS-Tween solution. Enhanced chemiluminescence was
employed using chemiluminescent reagents (Thermo Scientific, USA). The blots were detected
and analyzed by Image Quant LAS 4000 software (GE Healthcare Life Science, UK).
Bioinformatics and data analyses
DeCyderMS 2.0 differential analysis software (DeCyderMS, GE Healthcare Life Science, UK)
was used to analyze the data from LCMS/MS for protein identification and quantitation. The
intensities of peptide signals were analyzed using the PepDetect module. The peptides were
matched across different signal intensity maps among the tested conditions using the Pep-
Match module. The relative abundances of peptides were expressed as log2 intensities, with the
mass tolerance set to 0.5 Da and the retention time tolerance set to 1.0 min. All log2 intensities
of the sample were normalized to the ion intensity distribution of BSA. An average abundance
ratio> 2-fold higher than BSA external intensity control was determined to be an identified
and expressed protein with a significant standard t-test p-value< 0.05. The analyzed data from
DeCyderMS were submitted for a database search using Mascot software (Matrix Science, Lon-
don, UK). The data were searched against the NCBI database for protein identification. Data-
base interrogation was as follows: taxonomy (human or eukaryote), enzyme (trypsin), variable
modifications (carbamidomethyl, oxidation of methionine residues), mass values (monoisoto-
pic), protein mass (unrestricted), peptide mass tolerance (± 1.2 Da), fragment mass tolerance
(± 0.6 Da), peptide charge state (1+, 2+, and 3+), and max missed cleavages. Group-to-group
comparisons were performed by linear regression. Statistical analyses were performed in R
using the limma, gplots, VennDiagram and statmod packages. We used the lmFit and eBayes
functions in limma to compare groups and calculate moderated t-statistics. The false discovery
rate was controlled with the Benjamini-Hochberg method. The network analyses were per-
formed using Ingenuity software (Qiagen, Germany) and computes a network score according
to the fit of that network to the user-defined set of focus genes. The score is the −log10(p-
value) of a Fishers-exact test and hence indicates the likelihood of the focus genes in a network
are not being found together due to random chance.
Results
To identify protein markers ofMtb infection or clearance, we systematically assessed the intracel-
lular and secreted proteomes of PMA-activated THP-1 cells infected withMtbH37Rv and treated
with INH/RIF for one or five days compared to uninfected cells treated with INH/RIF (Fig 1).
The correlation between independent biological replicates was moderate (mean R2 value = 0.48),
regardless of the infection condition and time (S1 Fig). The total numbers of unique peptides and
named proteins identified from the LCMS/MS analysis were 4,440 and 3,291, respectively.
Patterns of protein expression during treated infection before and after
Mtb clearance identify potential markers of infection and clearance
After LC MS/MS analysis, 2,889 unique peptides from the intracellular proteome, 1,481 pep-
tides from the secreted proteome and 70 peptides common to both the intracellular and
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secreted proteomes were identified. Considering the total proteome (intracellular and secreted
combined), 91.3% (4,182/4,510) of peptides were common to all four treatmenttime compari-
son groups (Fig 2A). We classified peptides qualitatively according to the presence or absence
of expression during each condition and quantitatively according to significant differences in
level of expression for proteins that were present in both comparison groups. The definitions
used for classification are shown in Table 1. We note that the qualitative markers are wholly
Fig 1. General work flow. THP-1 cells were activated using 50 nM PMA and infected withMtbH37Rv. The
infected macrophages were treated with 3 μg of INH and 9 μg of RIF for 1 day (Day 1 Infected) (Mtb
remaining in the cells, i.e., infection stage) and 5 days (Day 5 Infected) (noMtb remaining in the cells 2 days
after clearance, i.e., clearance stage).Mtb clearance was confirmed by CFU determination at 3 days post-
infection. THP-1 cells treated with drugs (withoutMtb) for 1 day (Day 1 Uninfected) and 5 days (Day 5
Uninfected) post-infection were used as background controls. The culture supernatant and cell lysates were
collected. CFU counts were performed to confirm the clearance stage ofMtb in intracellular and extracellular
compartments from all experiments. Three biological replicates of the experiments were performed. The
proteomes were analyzed by GeLCMS/MS. A western blot was performed to validate the proteins identified
by GeLCMS/MS. The candidate clearance markers were compared to markers from patients treated with
anti-TB therapy from previous studies.
doi:10.1371/journal.pone.0134168.g001
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Fig 2. Proteome comparisons among conditions. (Figure A) Venn diagram of the proteome showing the
number of unique peptides detected according to each condition. The number in brackets refers to the
number of unique identifiable proteins to which the peptides match in the database. Consideration according
to presence/absence defined the qualitative markers, see also Table 1. (Figure B) Heatmap depicting the
level of expression (absent in blue, lowest in light pink, and highest in burgundy according to the key at the
Proteomic Analysis for Tuberculosis Clearance Markers
PLOS ONE | DOI:10.1371/journal.pone.0134168 July 27, 2015 7 / 16
absent/present and so represent the most robust markers for further follow-up in vivo, whereas
the quantitative markers are likely more useful in exploring the host-microbe interaction at
play as they provide additional plausible molecules that may be involved. The quantitative
markers should therefore be regarded as hypothesis generating in view of the multiple-hypoth-
eses tested.
We identified 15 peptides (13 named proteins) as “qualitative early infection markers”, 27
peptides (21 named proteins) as “qualitative sustained infection markers” and 10 peptides (9
named proteins) as “qualitative clearance markers” (Fig 2A). In addition to these peptides
whose qualitative presence/absence may identify infection/clearance states, we classified 67
peptides (42 named proteins), 7 peptides (6 named proteins), and 111 peptides (85 named pro-
teins) as quantitative early infection, sustained infection or clearance markers, respectively,
according to significant differences in quantitative expression after adjustment for multiple
comparisons (Fig 2B and S2 Table). In addition, we identified 46 peptides (30 named proteins)
as “suppressed infection markers” because these peptides were suppressed during infection
(day 1) but expressed in uninfected cells (day 1 and 5) and because their expression was
restored when the infection was cleared from cells by day 5 (Fig 2B and S2 Table). Examples of
the patterns of peptides/proteins in each class are shown in Fig 2C. Interestingly several mark-
ers are observed in both intra- and extra-cellular compartments, adding strength to their asso-
ciation. The raw data of intracellular (cell lysates) and extracellular (culture supernatant)
proteomes from all independent experiments, time points and conditions are available in the
supplementary tables (S3 and S4 Tables, respectively).
bottom left) across conditions as demarcated at the upper part of the heatmap. Protein names, or peptide
names if no match was found for a peptide, are shown to the left, where the symbols ‘<>‘ or ‘><‘ denote
detection in the secreted or intracellular proteome, respectively. Colored bars at the right of the heatmap
correspond to the classification into seven classes according to qualitative or quantitative criteria. (Figure C)
Examples of peptides from each class (denoted by color) of marker are shown with the expression level
according to the condition. Each replicate is denoted by a point, and boxes show the median (central line),
IQR (outer box) and range (whiskers) in the expression level. The y-axis refers to the protein to which the
peptide maps.
doi:10.1371/journal.pone.0134168.g002
Table 1. Classification of peptides according to qualitative or quantitative differences between acti-
vated THP-1 cells infected withM. tuberculosisH37Rv or left uninfected and sampled at Day 1 or Day 5.
Classes Qualitative definitions Quantitative definitions
Early infection
markers
Detectable in infected Day 1 cells only Significantly more highly expressed at
infected Day 1 vs uninfected Day 1 cells,
but not significantly more highly expressed




Detectable in infected Day 1 and Day 5
cells but not in uninfected cells
Significantly more highly expressed at
infected Day 1 vs uninfected Day 1 cells
and significantly more highly expressed at
infected Day 5 vs uninfected Day 5 cells
Clearance
markers
Detectable in infected Day 5 cells (i.e.
after clearance) only
Significantly more highly expressed at
infected Day 5 vs uninfected Day 5, but
not significantly more highly expressed at
infected Day 1 vs uninfected Day1 cells
Suppressed
infection marker
Suppressed in Day 1 infected cells but
present in uninfected cells and restored
in infected Day 5 (i.e. after clearance)
-
doi:10.1371/journal.pone.0134168.t001
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Network analyses of early infection, sustained infection and
microbiological clearance markers provide insight into the biology of the
host-pathogen interaction
A network analysis, leveraging protein-protein interaction data, of the clearance markers iden-
tified four networks of proteins that were significantly more likely than chance to be co-ordi-
nately associated (Fishers exact test −log10p> 2) amongst clearance markers (Fig 3). (i)
Thirteen proteins were identified in a network (−log10p = 21) centered on CD44 and CCND1,
which is enriched for disease and functional annotations related to the cell cycle (p = 1.7x10-6)
and with RNA post-transcriptional modification (p = 9x10-7) (Fig 3A); (ii) 12 proteins were in
a network (−log10p = 21) centered on IFN-β1, NF-κB, and MAPK (Fig 3B), which is enriched
for annotations related to with antimicrobial and inflammatory responses (p = 4.6x10-6); (iii)
11 proteins were in a network (−log10p = 17) centered on TP53 and TGF-β (Fig 3C), which is
enriched for annotations related to DNA replication, recombination and repair (p = 1.3x10-8),
cell-to-cell signaling and interaction (p = 1.5x10-7) and cell growth and proliferation
(p = 1.5x10-7); and (iv) 7 proteins were in a network (−log10p = 6) centered on CCL2, CCL4
and IFN-γ (Fig 3D), which is enriched for annotation related to cell death and survival
(p = 2x10-14), inflammatory response (p = 7.9x10-13), immune cell trafficking (p = 1.2x10-12).
Moreover, these networks are linked through common proteins, such as TLR, smad2/3, and
SMARCB1.
Among the early infection markers, two networks (−log10p = 31 and −log10p = 15) centered
on MYC and MET respectively were significant (S2A and S2B Fig). For sustained infection
markers, a network (−log10p = 21) converging on the NF-kB complex and TP53 was identified
(S2C Fig). For suppressed infection markers, one network (−log10p = 9) converging on BRCA1
and BRCA2 was identified (S2D Fig).
Validation of the presence of proteins by western blot analysis
To validate the proteins identified by GeLC MS/MS analysis, CAECAM18, a putative clearance
marker, was selected for western blot analysis. CAECAM18 was selected due to consistent
results among replicates (narrowest SD) and due to the lowest intensity of all clearance mark-
ers. We reasoned that validating the weakest clearance marker may support the sensitivity of
the MS/MS approach in the absence of the ability to perform western blots for all markers. β-
Actin was used as a normalizing control. The band intensity of the tested proteins corre-
sponded well to the LC MS/MS analysis results (Fig 4).
Discussion
Biomarkers indicatingMtb infection clearance could facilitate treatment monitoring for both
active TB and LTBI and identify individuals who successfully clear infection following expo-
sure. Several previous studies have identified proteomic markers for LTBI and active TB [9, 10,
12, 18]. Studies exploring TB treatment outcome markers have used clinical evidence and
microbiological evidence, particularly sputum microscopy and culture [19, 20]. Other studies
have applied molecular and serological markers for treatment monitoring [21–24]. However,
no studies have identified biomarkers of microbiologically-confirmed sterilizedMtb infection.
We used an in vitromodel of treatedMtb infection coupled with GeLC MS/MS to identify and
quantify peptides that may indicateMtb infection clearance. We compared the proteomes
between infection and clearance stages and found protein signatures that were associated with
early infection, sustained following infection, suppressed during infection or mycobacterial
clearance. Our findings provide a rich, list of candidates for further clinical validation asMtb
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Fig 3. Network analyses of protein clearancemarkers. The majority of clearance markers belong to one
of four networks. Network A centers on CD44 and CCND1 and consists of genes involved in the cell cycle
and RNA post-transcriptional modification (Figure A). Network B centers on IFNβ1, NF-κB, ERK1 and MAPK
and includes several additional genes involved in antimicrobial responses, such as TLR8 (Figure B).
Network C centers on TP53, and TGF-β and is associated with the cell cycle and with proliferation (Figure C).
Network D centers on CCL2, CCL4 and IFN-γ, which are associated with cell activation and migration and
which play a central role in tuberculosis (Figure D). Solid lines denote a direct protein-protein interaction,
such as binding; dotted lines denote other relationships, such as co-expression, regulation and activation,
phosphorylation or cleavage relationships. The intensity of protein expression is denoted in shades of red
proportionate to the level of expression.
doi:10.1371/journal.pone.0134168.g003
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clearance markers after anti-TB treatment. The identification of both qualitative and quantita-
tive markers further provide prioritization for these potential biomarkers.
Clearance markers expressed only after mycobacterial clearance from host cells and not
found during early infection of cells or in uninfected controls were associated with the cell
cycle, RNA post-transcriptional modification, antimicrobial responses, proliferation, cell
migration and movement. The networks for the cell cycle and for RNA post-transcriptional
modification centered on CD44 and CCND1. CD44 is a macrophage binding receptor that
mediates macrophage recruitment and protective immunity against TB [25]. CD44 knockout
mice have enhanced susceptibility toMtb infection due to a lower rate of neutrophil migration
[26]. Another chronic infection, hepatitis C virus infection, interferes with CCND1 (Cyclin
D1) expression and with the cell cycle; similar pathways may be involved inMtb infection [27].
Another network centered on chemokines (CCL2 and CCL4) and IFN-γ also supports a role
for cell recruitment and immunity in infection. AfterMtb clearance, the immune-related cellu-
lar activity and recruitment of infection-experienced cells appears to be greatly activated. The
network of proteins involved in antimicrobial and inflammatory response centered on IFN-β1,
NF-κB and MAPK is consistent with IFN-β1’s role againstMtb infection in infected macro-
phages [28] and in rhesus macaques [29]. VirulentMtb strains inhibit IFN-β1 expression [30].
Similarly, MAPK, which is involved in transducing TLR signals viamatrix metalloproteinase
(MMP) to recruit immune cells to an infected site [31], is also directly antagonized by a
19-kDa cell wall component ofMtb [32]. Several additional genes involved in antimicrobial
responses, such as TLR8, which is known to be involved in TB disease [33], were also upregu-
lated after clearance. The proteins from these networks were activated, indicating an increase
in the anti-Mtb response in infection-experienced cells. Another network of cell cycle- and pro-
liferation-related proteins centered on TP53 and TGF-β was enriched. TP53 and TGF-β have
functions in cytostasis, apoptosis and autophagy signaling pathways [34, 35]. The activation of
this network after clearance may indicate a homeostatic mechanism in infection-experienced
cells and it is concordant with the regulatory function of IFN-β1 in inhibiting the IFN- γ path-
way through the induction of IL-10 [36]. Taken together, infection-experienced cells appear to
adapt cellular processes to increase anti-Mtb responses, immune cell recruitment and homeo-
static mechanism after infection.
The expression pattern of clearance markers is consistent with some of these markers being
involved in trained innate immunity [37]. Notwithstanding the obvious differences between
our reductionist model here and in vivomodels which may be potentially confounded by the
different cell types, tissue compartments, patient comorbidities, we compared the candidate
clearance markers described here to transcriptional markers from patients treated for 26 weeks
treatment with anti-TB drug [38] and serum protein markers from patients treated with anti-
Fig 4. Validation of proteomic analysis by western blot using a monoclonal antibody to CAECAM 18. CAECAMwas uniquely detected in all 3
independent experiments.
doi:10.1371/journal.pone.0134168.g004
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TB therapy for eight weeks [16]. Notably, three of the clearance markers in our study, SSFA2,
PARP14, PSME4, overlap with transcriptional markers identified from TB patients after 26
weeks of treatment with anti-TB drugs [38]. Treatment with anti-TB drugs for 26 weeks may
better resemble our experiment in whichMtb was sterilized from cells, unlike eight week-
treated hosts [16], in whomMtbmay remain. In our study, SSFA2 (sperm-specific antigen 2)
was detected after mycobacterial clearance but was undetectable in infected or uninfected sam-
ples. Moreover, SSFA2 showed the largest fold change in expression. SSFA2 was associated
with caloric restriction in a rhesus macaque study [39]. However, its function, particularly in
immunity and infection, is unknown and requires further exploration.
The majority of the identified early infection markers belong to two networks of molecules
involved in antimicrobial response and apoptosis. The first network centers on hepcidin anti-
microbial peptide (HAMP) and Myc. Myc expression was shown to be associated with the
induction of TNF-α and IL-6 and suppression of intracellular mycobacterial growth [40]. Hep-
cidin may function as an antimicrobial peptide againstMtb [41, 42]. Another notable network
centered on CASP3 and Akt is linked to apoptosis regulation. CASP3 has been shown to be
involved in inducing apoptosis duringMtb infection [43], whereas Akt reduces apoptosis and
enhancesMtb survival [44]. The counteracting proteins associated with apoptosis may indicate
the competitive polarity of the host-Mtb interaction. Taken together, the proteins associated
with early infection portray the host’s response toMtb infection by inducing antimicrobial
response and apoptosis. Alternatively,Mtb induces host immune suppressors such as the anti-
apoptotic factor Akt to increase its intracellular survival. A network analysis of proteins that
continue to be expressed after infection (sustained infection markers) was observed and cen-
tered on NF-κB and TP53, both of which are also counteracting factors for apoptosis [45].
Therefore, the counteracting proteins for apoptosis, i.e., CASP3 vs. Akt and NF-κB vs. TP53,
both reflect the host-Mtb interaction in our study.
Additionally, we identified suppressed infection markers, i.e., the markers that were sup-
pressed during infection and restored afterMtb was cleared from cells. In contrast to the clear-
ance markers, the suppressed infection markers were restored after the cells experienced
infection. The network analysis of suppressed infection markers centered on BRCA1 and
BRCA2, which have roles in cell cycle control and DNA repair [46]. One possible interpreta-
tion is thatMtb infection suppressed these proteins to inhibit cell proliferation for its survival.
Recently, a clearance model ofMtb was suggested [37]. After alveolar macrophages are
exposed toMtb, they can eliminateMtb by phagocytosis and/or recruit other innate cells for
Mtb clearance, called “early clearance”. The inability to clearMtb by innate immune mecha-
nisms may lead to granuloma formation and adaptive host immune responses for clearance,
called “delayed clearance”. In addition to immune clearance,Mtb can be eliminated from host
tissue by anti-TB drugs. In this study, we used activated THP-1 cells infected withMtb and
treated with INH and RIF at the minimum serum concentration used in TB treatment. Unlike
pre- vs. post- treatment comparisons in vivo, our experiment used the drugs in all comparative
conditions, avoiding confounding drug effects on the proteome. Our model also focused on the
likely first cellular events in early clearance in the infected macrophages. Therefore, although
our study is limited by the use of an activated THP-1 cells model as opposed to a systemic host
model, this study allows the direct measurement of target cell-derived proteins. The simple cell
line experiment is advantageous because of the possibility to maintain a standard substrate for
three independent experiments in order to overcome constraints in reproducibility of GeLC
MS/MS. The THP-1 cell in our experiment was stimulated by PMA treatment followed by two
days resting in culture without PMA similar to the protocol suggested previously [47] which
was shown to enhance the similarity to primary monocyte derived macrophages (MDM). The
single cell type model also excludes interfering factors from other sources, for example, other
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tissues, as may be the case in human serum studies. Validation through the evaluation of
treated TB patients is hampered by difficulties in confidently assessingMtb clearance from tis-
sues. Hence, animal studies may be promising models forMtb clearance becauseMtb steriliza-
tion can be ensured from all organ tissues. However,Mtb is primarily a human pathogen, and
host-pathogen coevolution may result in discrepancies between animal and human models.
Future experiments may be adjusted to reflect the actual host environments, such as multicellu-
lar cell culture. Additionally, the use of multiple strains covering lineages ofMtb could over-
come the limitation of the use only H37Rv strain in our study. To reflect natural clearance,
host immune factors such as cytokines or antimicrobial peptides could be used in the model
instead of anti-TB drugs.
Although our clearance marker was not validated in the heterogeneous TB patients, a com-
parison with the markers found in the blood of 26 week-treated TB patients from a previous
study [37] showed some overlapping markers, thus supporting our results. Highly expressed
and potential clearance makers, such as SSFA2, can be further validated in a TB patient popula-
tion during treatment. The validation of blood proteins as clearance markers is hampered by
interfering substances from serum proteins and by many other cell types that may be less asso-
ciated with lung biology. However, blood samples are a practical for determiningMtb clearance
because they are normally collected to test alongside other general tests. Sputum and bronch-
oalveolar lavage, which are more reflective of the lung response toMtb and hence clearance,
can also be used to validate the clearance markers in further studies. We envisage that the use
of clearance markers in combination or patterns may increase their sensitivity in clinically het-
erogeneous samples. Alternatively, the combination of suppressed infection markers and clear-
ance markers may increase the ability to assess clearance.
Differentiation between people who have latentMtb versus people were previously infected
withMtb (cleared case) could contribute to better TB and LTBI treatment. Such a tool or
marker could potentially make mass treatment of LTBI in endemic settings feasible by narrow-
ing the target group of LTBI patients who require treatment. Such markers may also help assess
anti-TB drug and vaccine development.
In summary, several mechanisms of interaction between activated THP-1 cells andMtb
were identified. After cells experience infection, activated proteins associated with several
mechanisms againstMtb infection, cell development and recruitment were found. The compet-
itive polarity of apoptosis between host andMtb was shown. We identified several proteins
that could potentially be used as biomarkers for TB treatment monitoring.
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(TIF)
S2 Fig. Network analyses of early- (A-B), sustained- (C), and suppressed- infection markers
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HAMP and MYC (Figure A). Network B centers on CASP3 vs. Akt (Figure B) and Network C
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in the apoptosis pathway. Network D centers on BRCA1 and BRCA2 (Figure D). The intensity
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